Bio-Bridge Science, Inc., a development stage biotechnology company, engages in the commercial development of vaccines for the prevention and treatment of human infectious diseases. The company is developing and commercializing HIV-PV Vaccine I to prevent and treat infection by the human immunodeficiency virus (HIV). It develops HIV vaccines for both preventive and therapeutic purposes. HIV-PV Vaccine I is not yet approved for Phase I clinical trials. The company holds license for the HIV-PV Vaccine I technology with respect to China, the United States, and Japan. This license entrusts the company with the right to use this technology in various fields for treating HIV; human papillomavirus infection; and mucosal tumors, such as colonic and cervical cancers. Bio-Bridge Science was founded in 2002 and is headquartered in Oak Brook, Illinois.